Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 2,193,338 shares of Common stock, par value $0.01 ("Common Stock") of agilon health, inc. (the "Issuer") held directly by North Peak Capital Partners, LP, (2) 18,382,413 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 9,840,951 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 1,555,234 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,581,604 Common Stock outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the U.S. Securities and Exchange Commission (the "Commission") on November 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 2,193,338 shares of Common Stock held directly by North Peak Capital Partners, LP, (2) 18,382,413 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 9,840,951 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 1,555,234 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,581,604 Common Stock of the Issuer outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,581,604 Common Stock of the Issuer outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,581,604 Common Stock of the Issuer outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,581,604 Common Stock of the Issuer outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,581,604 Common Stock of the Issuer outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 2,193,338 shares of Common Stock held directly by North Peak Capital Partners, LP, (2) 18,382,413 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 9,840,951 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 1,555,234 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,581,604 Common Stock of the Issuer outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 2,193,338 shares of Common Stock held directly by North Peak Capital Partners, LP, (2) 18,382,413 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 9,840,951 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 1,555,234 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,581,604 Common Stock of the Issuer outstanding as of October 30, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 4, 2025.


SCHEDULE 13G



 
North Peak Capital Management, LLC
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Managing Member
Date:11/13/2025
 
North Peak Capital GP, LLC
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager
Date:11/13/2025
 
North Peak Capital Partners, LP
 
Signature:North Peak Capital GP, LLC
Name/Title:General Partner
Date:11/13/2025
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager
Date:11/13/2025
 
North Peak Capital Partners II, LP
 
Signature:North Peak Capital GP, LLC
Name/Title:General Partner
Date:11/13/2025
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager
Date:11/13/2025
 
North Peak Capital Alpha Fund, LP
 
Signature:North Peak Capital GP, LLC
Name/Title:General Partner
Date:11/13/2025
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager
Date:11/13/2025
 
North Peak Capital Ultra Fund, LP
 
Signature:North Peak Capital GP, LLC
Name/Title:General Partner
Date:11/13/2025
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager
Date:11/13/2025
 
Michael Kevin Kahan
 
Signature:/s/ Michael Kahan
Name/Title:Michael Kahan
Date:11/13/2025
 
Jeremy Steven Kahan
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan
Date:11/13/2025
Exhibit Information

Exhibit 99.1. Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on August 29, 2025, by the Reporting Persons with the SEC).